No increased risk of myocardial infarction among patients with ulcerative colitis or Crohn's disease.

PubWeight™: 1.05‹?› | Rank: Top 15%

🔗 View Article (PMC 3183342)

Published in Clin Gastroenterol Hepatol on July 13, 2011

Authors

Mark T Osterman1, Yu-Xiao Yang, Colleen Brensinger, Kimberly A Forde, Gary R Lichtenstein, James D Lewis

Author Affiliations

1: Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA. mark.osterman@uphs.upenn.edu

Articles citing this

Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death--a Danish nationwide cohort study. PLoS One (2013) 1.78

Comparison of inflammation, arterial stiffness and traditional cardiovascular risk factors between rheumatoid arthritis and inflammatory bowel disease. J Inflamm (Lond) (2014) 1.00

Inflammatory bowel disease and thromboembolism. World J Gastroenterol (2014) 0.97

Enteropathic spondyloarthritis: from diagnosis to treatment. Clin Dev Immunol (2013) 0.87

Steroid exposure, acute coronary syndrome, and inflammatory bowel disease: insights into the inflammatory milieu. Am J Med (2014) 0.78

Risk of Ischaemic Heart Disease in Patients with Inflammatory Bowel Disease: Cohort Study Using the General Practice Research Database. PLoS One (2015) 0.78

Effect of the Diagnosis of Inflammatory Bowel Disease on Risk-Adjusted Mortality in Hospitalized Patients with Acute Myocardial Infarction, Congestive Heart Failure and Pneumonia. PLoS One (2016) 0.77

Cardiovascular complications in inflammatory bowel disease. Curr Drug Targets (2015) 0.77

Cardiovascular involvement in inflammatory bowel disease: Dangerous liaisons. World J Gastroenterol (2015) 0.75

Risk of cardiovascular disease in inflammatory bowel disease. Exp Ther Med (2016) 0.75

Care of inflammatory bowel disease patients in remission. Gastroenterol Rep (Oxf) (2016) 0.75

Cardiovascular disease in immune-mediated inflammatory diseases: A cross-sectional analysis of 6 cohorts. Medicine (Baltimore) (2017) 0.75

Eosinophilia and Ulcerative Colitis Associated with Eosinophilic Myocarditis. Tex Heart Inst J (2017) 0.75

Role of Inflammatory Diseases in Hypertension. High Blood Press Cardiovasc Prev (2017) 0.75

Articles cited by this

Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med (2005) 28.21

Inflammation and atherosclerosis. Circulation (2002) 20.77

Risk of myocardial infarction in patients with psoriasis. JAMA (2006) 9.42

Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation (2003) 6.62

Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol (1997) 6.10

High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum (2001) 5.87

Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet (2010) 5.63

Antibiotics and risk of subsequent first-time acute myocardial infarction. JAMA (1999) 5.37

Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum (2001) 5.36

Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ (1995) 4.50

Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology (2004) 3.57

Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Epidemiology (2001) 3.51

The relationship between time since registration and measured incidence rates in the General Practice Research Database. Pharmacoepidemiol Drug Saf (2005) 3.24

Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut (2004) 2.55

Inflammation and coagulation in inflammatory bowel disease: The clot thickens. Am J Gastroenterol (2006) 2.50

Acute respiratory-tract infections and risk of first-time acute myocardial infarction. Lancet (1998) 2.39

Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum (1999) 2.36

The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost (2001) 2.31

Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation (2002) 2.28

Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses' health study. Arthritis Rheum (2009) 2.26

Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther (2008) 2.15

Validity and completeness of the General Practice Research Database for studies of inflammatory bowel disease. Pharmacoepidemiol Drug Saf (2002) 2.12

Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am J Cardiol (2004) 2.11

Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol (2008) 2.09

Antirheumatic drug use and the risk of acute myocardial infarction. Arthritis Rheum (2006) 1.99

Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum (2006) 1.95

The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study. Clin Gastroenterol Hepatol (2007) 1.91

Inflammatory bowel disease is associated with an increased incidence of cardiovascular events. Am J Gastroenterol (2011) 1.88

Survival and cause-specific mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen County. Gastroenterology (2003) 1.84

Mortality in inflammatory bowel disease: a population-based cohort study. Gastroenterology (2003) 1.83

Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum (2007) 1.67

Survival and causes of death in patients with inflammatory bowel disease: a population-based study. Gastroenterology (1992) 1.65

Survival and cause-specific mortality in inflammatory bowel disease: a population-based cohort study. Gastroenterology (1996) 1.51

The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis. Arthritis Rheum (2008) 1.44

Inflammatory bowel disease and the risk of fracture. Gastroenterology (2003) 1.41

The risk of myocardial infarction associated with antihypertensive drug treatment in persons with uncomplicated essential hypertension. Pharmacotherapy (1996) 1.38

General and cancer specific mortality of a population based cohort of patients with inflammatory bowel disease: the Florence Study. Gut (1998) 1.26

Antihypertensive drugs and fatal myocardial infarction in persons with uncomplicated hypertension. Epidemiology (1997) 1.13

CD40 and its ligand in atherosclerosis. Trends Cardiovasc Med (2007) 0.98

Articles by these authors

Linking long-term dietary patterns with gut microbial enterotypes. Science (2011) 17.30

Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med (2005) 14.50

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 14.14

Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA (2006) 9.53

Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med (2013) 9.44

The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology (2002) 4.98

Sampling and pyrosequencing methods for characterizing bacterial communities in the human gut using 16S sequence tags. BMC Microbiol (2010) 4.97

Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology (2004) 4.26

Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology (2009) 3.73

Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA (2011) 3.58

Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology (2004) 3.57

The human gut virome: inter-individual variation and dynamic response to diet. Genome Res (2011) 3.32

Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology (2013) 3.28

Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol (2002) 3.01

Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology (2011) 2.96

Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc (2006) 2.73

Mortality associated with medical therapy versus elective colectomy in ulcerative colitis: a cohort study. Ann Intern Med (2014) 2.73

Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology (2007) 2.55

A cognitive neuroscience-based computerized battery for efficient measurement of individual differences: standardization and initial construct validation. J Neurosci Methods (2009) 2.55

Rapid evolution of the human gut virome. Proc Natl Acad Sci U S A (2013) 2.53

Retrospective drug utilization review, prescribing errors, and clinical outcomes. JAMA (2003) 2.51

Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA (2012) 2.51

Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol (2004) 2.45

Use of abdominopelvic computed tomography in emergency departments and rates of urgent diagnoses in Crohn's disease. Clin Gastroenterol Hepatol (2011) 2.40

Hospitalization and mortality rates from peptic ulcer disease and GI bleeding in the 1990s: relationship to sales of nonsteroidal anti-inflammatory drugs and acid suppression medications. Am J Gastroenterol (2002) 2.39

The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol (2007) 2.32

Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Gastroenterology (2012) 2.26

Development of an internet-based cohort of patients with inflammatory bowel diseases (CCFA Partners): methodology and initial results. Inflamm Bowel Dis (2012) 2.23

Videofluoroscopic studies of swallowing dysfunction and the relative risk of pneumonia. AJR Am J Roentgenol (2003) 2.20

Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol (2006) 2.16

Idiopathic gastric acid hypersecretion presenting as a diarrheal disorder and mimicking both Zollinger-Ellison syndrome and Crohn's disease. Eur J Gastroenterol Hepatol (2005) 2.15

Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology (2005) 2.15

Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum (2012) 2.15

Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology (2006) 2.14

Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study. Am J Ophthalmol (2012) 2.14

Validity and completeness of the General Practice Research Database for studies of inflammatory bowel disease. Pharmacoepidemiol Drug Saf (2002) 2.12

AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology (2010) 2.09

An optimized patient-reported ulcerative colitis disease activity measure derived from the Mayo score and the simple clinical colitis activity index. Inflamm Bowel Dis (2014) 2.05

Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis (2008) 2.04

Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy. Arthritis Care Res (Hoboken) (2015) 2.03

Detection of proximal adenomatous polyps with screening sigmoidoscopy: a systematic review and meta-analysis of screening colonoscopy. Arch Intern Med (2003) 2.02

Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med (2008) 1.99

Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl (2004) 1.95

Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology (2003) 1.94

Trends in the use of biologic agents among rheumatoid arthritis patients enrolled in the US medicare program. Arthritis Care Res (Hoboken) (2013) 1.92

Risk of kidney injury following oral phosphosoda bowel preparations. J Am Soc Nephrol (2007) 1.89

Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevation. Liver Transpl (2005) 1.87

Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care (2011) 1.83

Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut (2011) 1.80

Immunosuppressant medications and mortality in inflammatory bowel disease. Am J Gastroenterol (2008) 1.80

Time trends in therapies and outcomes for adult inflammatory bowel disease, Northern California, 1998-2005. Gastroenterology (2009) 1.74

The effects of infliximab maintenance therapy on health-related quality of life. Am J Gastroenterol (2003) 1.72

Incidence and prevalence of inflammatory bowel disease in a Northern California managed care organization, 1996-2002. Am J Gastroenterol (2008) 1.72

A randomized, controlled, double-blind trial of patient-controlled sedation with propofol/remifentanil versus midazolam/fentanyl for colonoscopy. Anesth Analg (2008) 1.71

Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study. J Natl Cancer Inst (2012) 1.69

Cancer incidence in The Health Improvement Network. Pharmacoepidemiol Drug Saf (2009) 1.65

Archaea and fungi of the human gut microbiome: correlations with diet and bacterial residents. PLoS One (2013) 1.64

Non-viral causes of hepatocellular carcinoma. World J Gastroenterol (2010) 1.63

Heterotopic pancreas presenting as dysphagia. Am J Gastroenterol (2002) 1.63

Agreement between GPRD smoking data: a survey of general practitioners and a population-based survey. Pharmacoepidemiol Drug Saf (2004) 1.61

Validity of The Health Improvement Network (THIN) for epidemiologic studies of hepatitis C virus infection. Pharmacoepidemiol Drug Saf (2009) 1.61

Hypervariable loci in the human gut virome. Proc Natl Acad Sci U S A (2012) 1.58

A prospective, randomized, comparative trial evaluating respiratory depression during patient-controlled versus anesthesiologist-administered propofol-remifentanil sedation for elective colonoscopy. Gastrointest Endosc (2010) 1.57

A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol (2010) 1.55

A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology (2004) 1.51

Angiotensin-converting enzyme inhibitor therapy and colorectal cancer risk. J Natl Cancer Inst (2014) 1.50

Association between proton pump inhibitor use and spontaneous bacterial peritonitis. Dig Dis Sci (2007) 1.50

Ineffective motility is not a marker for gastroesophageal reflux disease. Am J Gastroenterol (2003) 1.50

Anti-TNF antibodies for Crohn's disease--in pursuit of the perfect clinical trial. N Engl J Med (2007) 1.50

Interobserver agreement among endosonographers for the diagnosis of neoplastic versus non-neoplastic pancreatic cystic lesions. Gastrointest Endosc (2003) 1.49

Structure-constrained sparse canonical correlation analysis with an application to microbiome data analysis. Biostatistics (2012) 1.49

Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population. Hepatology (2004) 1.49

Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Clin North Am (2002) 1.49

Communication outcomes in audiologic reporting. J Am Acad Audiol (2011) 1.48

Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA (2013) 1.45

Relationship between coronary angioplasty laboratory volume and outcomes after hospital discharge. Am Heart J (2002) 1.44

Antibiotic exposure and the risk for depression, anxiety, or psychosis: a nested case-control study. J Clin Psychiatry (2015) 1.43

Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum (2012) 1.43

Histologic predictors of fibrosis progression in liver allografts in patients with hepatitis C virus infection. Clin Gastroenterol Hepatol (2009) 1.41

Hypochlorhydria and achlorhydria are associated with false-positive secretin stimulation testing for Zollinger-Ellison syndrome. Pancreas (2013) 1.41

Ascites after liver transplantation--a mystery. Liver Transpl (2004) 1.40

Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol (2011) 1.39

A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology (2006) 1.39

Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response. Hepatology (2003) 1.39

Development of an abbreviated schizophrenia quality of life scale using a new method. Neuropsychopharmacology (2002) 1.36

Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol (2003) 1.35

Quality indicators for inflammatory bowel disease: development of process and outcome measures. Inflamm Bowel Dis (2013) 1.33

The impact of increased body mass index on the clinical course of Crohn's disease. Clin Gastroenterol Hepatol (2006) 1.32

Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems. Pharmacoepidemiol Drug Saf (2011) 1.30

Nutrition environments in corner stores in Philadelphia. Prev Med (2012) 1.30